Abstract: This disclosure provides lentiviral vectors containing an attachment incompetent fusogenic polypeptide and a heterologous targeting polypeptide. Also provided are lentiviral packaging constructs, lentiviral packaging systems, and lentiviral gene delivery systems. Finally, methods of transducing a cell and methods of targeting a gene to a cell or tissue using the disclosed lentiviral vectors and systems are also provided.
Type:
Grant
Filed:
January 16, 2004
Date of Patent:
August 15, 2006
Assignee:
The Salk Institute for Biological Studies
Inventors:
Brian Spencer, Robert Marr, Inder M. Verma
Abstract: Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, and anti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.
Type:
Grant
Filed:
October 21, 2003
Date of Patent:
July 18, 2006
Assignee:
The General Hospital Corporation
Inventors:
David T. MacLaughlin, Joseph P. Vacanti, Patricia K. Donahoe, Peter T. Masiakos
Abstract: The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF nucleic acid molecules, including those that encode canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins, respectively; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds.
Type:
Grant
Filed:
August 13, 2002
Date of Patent:
July 18, 2006
Assignee:
Heska Corporation
Inventors:
Gek-Kee Sim, Shumin Yang, Matthew J. Dreitz, Ramani S. Wonderling
Abstract: The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles of peptides.
Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
Type:
Grant
Filed:
June 20, 2003
Date of Patent:
June 27, 2006
Assignee:
Aegera Therapeutics, Inc.
Inventors:
Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston
Abstract: Amino acid sequences and nucleotide sequences relating to PDEXV are described. In a preferred aspect, the amino acid sequence comprises the sequence presented as SEQ ID NO:1.
Abstract: Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.
Abstract: The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF nucleic acid molecules, including those that encode canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins, respectively; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds.
Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
Type:
Grant
Filed:
September 1, 2000
Date of Patent:
December 20, 2005
Assignee:
University of Ottawa
Inventors:
Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird
Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
Type:
Grant
Filed:
October 26, 1999
Date of Patent:
October 25, 2005
Assignees:
Licentia Ltd, Seppo Yla-Herttuala, Ludwig Institute of Cancer Research
Inventors:
Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen
Abstract: Endothelial protein C receptor (EPCR) is found primarily on endothelial cells of large vessels. EPCR translocates from the plasma membrane surface to the nucleus. Molecules which bind to EPCR can be carried from the plasma membrane surface to the nucleus. These molecules include antibodies to EPCR and activated protein C. Protein C, which also binds to EPCR, can be internalized by endothelial cells, but does not enter the nucleus. Thus, EPCR translocation from the plasma membrane to the nucleus provides a means of delivering nucleic acid such as DNA, proteins such as transcription factors, diagnostic agents or other types of drugs to the nucleus of endothelial cells, particularly those on large blood vessels. Conjugates of the materials to be delivered to the nucleus can be formed by ionic or covalent coupling. For example, proteins, including fusion proteins, can be directly conjugated to an anti-EPCR monoclonal antibody.
Abstract: A plasmid has been isolated from Rhodococcus erythropolis strain AN12 comprising a unique replication protein. The replication protein may be used in a variety of cloning and expression vectors and particularly in shuttle vectors for the expression of heterologous genes in Rhodococcus sp.
Type:
Grant
Filed:
December 5, 2001
Date of Patent:
September 27, 2005
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Michael G. Bramucci, Qiong Cheng, Kristy N. Kostichka, Jean-Francois Tomb
Abstract: Conditionally-immortalized human mesencephalon cell lines are provided. Such cell lines, which may be clonal, may be used to generate neurons, including dopaminergic neurons. The cell lines and/or differentiated cells may be used for the development of therapeutic agents to prevent and treat a variety of neurological diseases such as Parkinson's disease. The cell lines and/or differentiated cells may also be used in assays and for the general study of mesencephalon cell development and differentiation.
Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
Type:
Grant
Filed:
May 19, 1999
Date of Patent:
June 7, 2005
Assignee:
Canji, Inc.
Inventors:
Douglas Antelman, Richard J. Gregory, Kenneth N. Wills
Abstract: The present invention relates to capsules encapsulating cytochrome P450 producing cells and cytochrome P450 producing retroviral packaging cells. Furthermore, the present invention relates to the treatment of cancer or any other relevant disease with said capsules and to the use of said capsules for the preparation of a pharmaceutical composition for said treatment.
Type:
Grant
Filed:
September 24, 1998
Date of Patent:
May 17, 2005
Assignees:
GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH, Bavarian Nordic A/S
Inventors:
Walter H. Günzburg, Peter Karle, Robert Saller, Brian Salmons, Matthias Löhr, Peter Müller
Abstract: The invention provides TCCV-1 or TCCV-2 from human, reagents related thereto including polynucleotides encoding TCCV-1 or TCCV-2, purified polypeptides, and specific antibodies. Methods of making and using these reagents, in particular, methods for screening compounds which modulate TCCV-1 or TCCV-2 activity are provided. Also provided are methods of diagnosis and kits.
Type:
Grant
Filed:
April 29, 2003
Date of Patent:
May 17, 2005
Assignee:
Syntex (U.S.A.) LLC
Inventors:
Paul Shartzer Dietrich, Joseph Gerrard McGivern
Abstract: The invention relates to recombinant DNA constructs, a method for producing a recombinant biologically active protein in vivo in the urine of a non-human mammal using a kidney-specific promoter, such as the uromodulin promoter, and the transgenic non-human mammals that serve as urine-based bioreactors for protein production.
Abstract: Isolated nucleic acid molecules are provided which encode Fkhsf, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic acid sequences disclosed herein (as well as mutant forms thereof), numerous molecules may be identified which modulate the immune system.
Type:
Grant
Filed:
April 2, 2002
Date of Patent:
April 26, 2005
Assignee:
Darwin Discovery Ltd.
Inventors:
Mary E. Brunkow, Eric W. Jeffery, Kathryn A. Hjerrild, Fred Ramsdell
Abstract: Methods and compositions are described that provide scaffolds for the support of cells. The scaffolds of the present invention have structural uniformity and desirable mechanical properties that make them suitable for a variety of uses, including uses for in vitro tissue regeneration or in vivo tissue or organ replacement. A method is described for controlling three-dimensional structure of the hydrogel/cell constructs under tissue culture environment.
Type:
Grant
Filed:
February 23, 1999
Date of Patent:
March 29, 2005
Assignee:
The Regents of the University of Michigan
Abstract: The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions.